Year: 2008
Type: review
Abstract: Insulin therapy in diabetes, both at on-set and after several years ’ duration, isprimarily directed to maintain near-normoglycemia to prevent the onset and/or delay progression of long-term complications (1,2). However, it is im-portant that regimens of insulin therapy are designed not only to aim at near-normalizing blood glucose, but also to minimize the risk of hypoglycemia. Sub-jects with type 1 diabetes continuously drift between hyperglycemia and hypo-glycemia. If the former prevails, long-term complications are frequently expected (1). On the other hand, hypo-glycemia is not only dangerous and un-pleasant, but may over time lead to the syndrome of hypoglycemia unawareness (3). This is relevant in type 1 diabetes but also in type 2 diabetes, since over time, many type 2 diabetic subjects develop progressive pancreatic -cell dysfunction requiring insulin therapy. Because in sub-jects with advanced type 2 diabetes the neuroendocrine responses to hypoglyce-mia are as abnormal as in type 1 diabetic patients (4), insulin therapy may become responsible for frequent and/or severe hy-poglycemia in type 2 diabetic patients as well. The goal of minimizing the risk of hy-poglycemia while achieving good glyce-mic control is feasible as long as 1) a rational plan of insulin therapy is adopted, 2) blood glucose is properly monitored, 3) blood glucose targets are individualized, and 4) education pro-grams are widely implemented. In the present article, the importance of the use of insulin analogs as a key tool to achieve good glycemic control and pre-vent hypoglycemia is emphasized.
Source: Diabetes Care
DOI: 10.2337/dc08-s227
Institution: University of Perugia
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2112217619
